Applied Nutrition Flexes Its Protein Power

THE GIST

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.

Applied Nutrition is selling protein like everyone suddenly joined the gym. The growth is real, the guidance is up, and the only thing looking heavier than demand is the whey bill.

WHAT HAPPENED

Applied Nutrition lifted its outlook after a strong year of trading across its markets and sales channels.

The Liverpool-based sports nutrition group now expects revenue for the year to July 31, 2026, to rise 50% to about £160 million (about $217 million), up from £107 million a year earlier. That is ahead of company-compiled market expectations of £148.4 million.

Adjusted EBITDA is expected to rise 40% to about £43.3 million, also ahead of the previous consensus figure of £42 million. The company said trading since June 1 had remained strong, with sustained demand across the group’s regions and channels.

Investors initially liked the update. Applied Nutrition shares rose as much as 9% in London trading, reaching 350.5p, before giving back some of those gains later in the day.

The company also guided for another year of growth. For the year ending July 2027, it expects revenue of around £205 million, comfortably ahead of market forecasts of £186.2 million. Adjusted EBITDA is expected to rise to about £49 million, versus consensus of £47.7 million.

Applied Nutrition ended the financial year with net cash of £15.9 million, despite buying assets from US sports nutrition manufacturer Nutrablend and investing in extra production capacity.

The Nutrablend deal, announced in June, cost $16 million in cash and included a manufacturing and logistics site in Buffalo, New York, plus the Basic Supplements and GR8 Lifestyle brands.

The company sells products under Applied Nutrition, ABE, BodyFuel and Endurance. It offers more than 120 products and distributes in more than 85 countries.

WHY IT MATTERS

Applied Nutrition is riding one of the cleaner consumer trends around: people want more protein.

That demand is coming from gym users, athletes, health-conscious shoppers and, increasingly, consumers using weight-loss drugs who are trying to preserve muscle while eating less. Protein powders, ready-to-drink shakes, pre-workout products and functional drinks have moved from niche gym bags into mainstream shopping baskets.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

That is exactly where Applied Nutrition wants to be. The company is not trying to sell a complicated turnaround story. It is selling tubs, drinks and sachets into a global health-and-fitness market that keeps getting bigger.

The business model has worked because it combines brand, distribution and speed. Applied Nutrition can move quickly into retailers, gyms and online channels, while adjusting its product mix around what consumers are buying. The relaunch of Critical Whey is part of that playbook, tapping into demand for whey-based products at a time when protein has become the consumer goods sector’s favorite magic word.

The US is the bigger prize. The Nutrablend acquisition gives Applied Nutrition a manufacturing and logistics base in Buffalo, which should help it scale in a market where sports nutrition is already large and still growing. It also creates opportunities in white-label production, where the company can manufacture for other brands as well as push its own.

That is why analysts are focused on US expansion, new retailer deals and licensing opportunities. The Sour Patch license gives Applied Nutrition another route into consumers who might not think of themselves as protein-powder people but will buy a familiar candy-flavored performance product if it looks fun enough.

The problem is that growth does not get a free pass from input costs. Whey prices are rising, and whey-based products are becoming a bigger part of Applied Nutrition’s mix. That means revenue can keep climbing while margins edge lower.

The company has already warned that adjusted EBITDA margins are expected to decline slightly in 2027. Peel Hunt estimates the margin could fall to 24.1% from 27.1% in the year just ended, partly because of whey inflation and partly because the US business is expected to become a larger share of the group.

That is not a disaster. A business growing revenue from £160 million to £205 million can absorb some margin pressure if the top line keeps running. But investors will not ignore it forever. Protein hype is good. Profit conversion is better.

There is also a geopolitical wrinkle. Applied Nutrition previously warned that Middle East sales volumes could be affected by the Iran war, but the latest update suggests the company has still managed to grow strongly across international markets, including Latin America and the Middle East.

WHAT’S NEXT

Applied Nutrition will report full-year results on or around November 16, when investors will get a clearer view of margins, cash generation, US progress and how much whey inflation is biting.

The next test is whether management can turn strong demand into scalable international growth without giving away too much profitability. The Buffalo site, retailer wins, licensing deals and Critical Whey relaunch will all be watched closely.

Applied Nutrition has momentum, cash and a product category with serious cultural tailwinds. The market just wants to know whether this protein shake still tastes good after the whey bill arrives.